Search

Your search keyword '"Morris, Patrick G."' showing total 462 results
Start Over Author "Morris, Patrick G."
462 results on '"Morris, Patrick G."'

2. Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer

Author

Cosgrove, Nicola, Eustace, Alex J., O’Donovan, Peter, Madden, Stephen F., Moran, Bruce, Crown, John, Moulton, Brian, Morris, Patrick G., Grogan, Liam, Breathnach, Oscar, Power, Colm, Allen, Michael, Walshe, Janice M., Hill, Arnold D., Blümel, Anna, O’Connor, Darren, Das, Sudipto, Milewska, Małgorzata, Fay, Joanna, Kay, Elaine, Toomey, Sinead, Hennessy, Bryan T., and Furney, Simon J.

Published
2023
Full Text
View/download PDF

5. High frequency and mortality of head and neck malignancy in organ transplant recipients in Ireland – A national cohort study

Author

Conlon, Eoin, Fitzgerald, Conall, Hintze, Justin, Elhassan, Elhussein A.E., Sexton, Donal J., O'Leary, Eamonn, O'Kelly, Patrick, O'Neill, Jim O., Egan, Jim, Houlihan, Diarmaid D., Murray, Deirdre, McCormick, P. Aiden, Morris, Patrick G., Raghallaigh, Siona Ni, Little, Dilly, Conlon, Peter J., Moloney, Fergal J., and O'Neill, James Paul

Published
2023
Full Text
View/download PDF

7. Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.

Author

Albanell, Joan, primary, Williams, Amy, additional, Martínez, Maria Teresa, additional, Ritzen, Hanna, additional, Paris, Lorena, additional, O'Connor, Miriam, additional, De la Cruz Merino, Luis, additional, Santaballa, Ana, additional, Martinez-Jañez, Noelia, additional, Moreno Antón, Fernando, additional, Fernández, Isaura, additional, Alarcón Company, Jesús, additional, Guerra, Juan Antonio, additional, Ruiz-Borrego, Manuel, additional, Morris, Patrick G., additional, Portela, Marta, additional, Herranz, Jesús, additional, Caballero, Rosalia, additional, Bergqvist, Mattias, additional, and Rojo Todo, Federico Gustavo, additional

Published
2024
Full Text
View/download PDF

12. A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.

Author

Gucalp, Ayca, Zhou, Xi K, Cook, Elise D, Garber, Judy E, Crew, Katherine D, Nangia, Julie R, Bhardwaj, Priya, Giri, Dilip D, Elemento, Olivier, Verma, Akanksha, Wang, Hanhan, Lee, J Jack, Vornik, Lana A, Mays, Carrie, Weber, Diane, Sepeda, Valerie, O'Kane, Holly, Krasne, Margaret, Williams, Samantha, Morris, Patrick G, Heckman-Stoddard, Brandy M, Dunn, Barbara K, Hudis, Clifford A, Brown, Powel H, and Dannenberg, Andrew J

Subjects
Humans, Carcinoma, Intraductal, Noninfiltrating, Breast Neoplasms, Neoplasm Invasiveness, Precancerous Conditions, Fibrocystic Breast Disease, Docosahexaenoic Acids, Prognosis, Follow-Up Studies, Double-Blind Method, Gene Expression Profiling, Middle Aged, Female, Biomarkers, Tumor, Breast Cancer, Estrogen, Clinical Trials and Supportive Activities, Aging, Obesity, Prevention, Complementary and Integrative Health, Cancer, Nutrition, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Obesity, a cause of subclinical inflammation, is a risk factor for the development of postmenopausal breast cancer and is associated with poorer cancer outcomes. Docosahexaenoic acid (DHA), an omega-3 fatty acid, possesses anti-inflammatory properties. We hypothesized that treatment with DHA would reduce the expression of proinflammatory genes and aromatase, the rate-limiting enzyme for estrogen biosynthesis, in benign breast tissue of overweight/obese women. A randomized, placebo-controlled, double-blind phase II study of DHA given for 12 weeks to overweight/obese women with a history of stage I-III breast cancer, DCIS/LCIS, Paget's disease, or proliferative benign breast disease was carried out. In this placebo controlled trial, the primary objective was to determine whether DHA (1,000 mg by mouth twice daily) reduced breast tissue levels of TNFα. Secondary objectives included evaluation of the effect of DHA on breast tissue levels of COX-2, IL1β, aromatase, white adipose tissue inflammation, and gene expression by RNA-seq. Red blood cell fatty acid levels were measured to assess compliance. From July 2013 to November 2015, 64 participants were randomized and treated on trial (32 women per arm). Increased levels of omega-3 fatty acids in red blood cells were detected following treatment with DHA (P < 0.001) but not placebo. Treatment with DHA did not alter levels of TNFα (P = 0.71), or other biomarkers including the transcriptome in breast samples. Treatment with DHA was overall well-tolerated. Although compliance was confirmed, we did not observe changes in the levels of prespecified biomarkers in the breast after treatment with DHA when compared with placebo. Cancer Prev Res; 11(4); 203-14. ©2018 AACRSee related editorial by Fabian and Kimler, p. 187.

Published
2018

13. Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study

Author

Prior, Lisa, O’Dwyer, Richard, Farooq, Abdul Rehman, Greally, Megan, Ward, Cian, O’Leary, Connor, Aslam, Razia, Darwish, Waseem, Ahmed, Nada, Othman, Elly Che, Watson, Geoffrey, Kelly, Deirdre, Gleeson, Jack, Kiely, Lisa, Hassan, Anees, Walsh, Elaine M., O’Reilly, David, Jones, Alfred, Featherstone, Hannah, Lim, Marvin, Murray, Hazel, Hennessy, Bryan T., Smyth, Lillian M., Leonard, Gregory, Grogan, Liam, Breathnach, Oscar, Calvert, Paula, Horgan, Anne M., Coate, Linda, Jordan, Emmet J., O’Mahony, Deirdre, Gupta, Rajnish, Keane, Maccon M., Westrup, Jennifer, Duffy, Karen, O’Connor, Miriam, Morris, Patrick G., Kennedy, M. John, O’Reilly, Seamus, McCaffrey, John, Kelly, Catherine M., Carney, Desmond, Gullo, Giuseppe, Crown, John, Higgins, Michaela J., Walsh, Paul M., and Walshe, Janice M.

Published
2021
Full Text
View/download PDF

15. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Author

Mayer, Erica L, Dueck, Amylou C, Martin, Miguel, Rubovszky, Gabor, Burstein, Harold J, Bellet-Ezquerra, Meritxell, Miller, Kathy D, Zdenkowski, Nicholas, Winer, Eric P, Pfeiler, Georg, Goetz, Matthew, Ruiz-Borrego, Manuel, Anderson, Daniel, Nowecki, Zbigniew, Loibl, Sibylle, Moulder, Stacy, Ring, Alistair, Fitzal, Florian, Traina, Tiffany, Chan, Arlene, Rugo, Hope S, Lemieux, Julie, Henao, Fernando, Lyss, Alan, Antolin Novoa, Silvia, Wolff, Antonio C, Vetter, Marcus, Egle, Daniel, Morris, Patrick G, Mamounas, Eleftherios P, Gil-Gil, Miguel J, Prat, Aleix, Fohler, Hannes, Metzger Filho, Otto, Schwarz, Magdalena, DuFrane, Carter, Fumagalli, Debora, Theall, Kathy Puyana, Lu, Dongrui Ray, Bartlett, Cynthia Huang, Koehler, Maria, Fesl, Christian, DeMichele, Angela, and Gnant, Michael

Published
2021
Full Text
View/download PDF

18. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer

Author

Mezynski, M. Janusz, Farrelly, Angela M., Cremona, Mattia, Carr, Aoife, Morgan, Clare, Workman, Julie, Armstrong, Paul, McAuley, Jennifer, Madden, Stephen, Fay, Joanna, Sheehan, Katherine M., Kay, Elaine W., Holohan, Ciara, Elamin, Yasir, Rafee, Shereen, Morris, Patrick G., Breathnach, Oscar, Grogan, Liam, Hennessy, Bryan T., and Toomey, Sinead

Published
2021
Full Text
View/download PDF

22. Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis

Author

Seo, Bo Ri, Bhardwaj, Priya, Choi, Siyoung, Gonzalez, Jacqueline, Andresen Eguiluz, Roberto C, Wang, Karin, Mohanan, Sunish, Morris, Patrick G, Du, Baoheng, Zhou, Xi K, Vahdat, Linda T, Verma, Akanksha, Elemento, Olivier, Hudis, Clifford A, Williams, Rebecca M, Gourdon, Delphine, Dannenberg, Andrew J, and Fischbach, Claudia

Subjects
Medical Biotechnology, Biomedical and Clinical Sciences, Breast Cancer, Nutrition, Obesity, Cancer, Prevention, 2.1 Biological and endogenous factors, Aetiology, Stroke, Oral and gastrointestinal, Cardiovascular, Adipose Tissue, Animals, Breast Neoplasms, Cell Differentiation, Cell Transformation, Neoplastic, Cells, Cultured, Extracellular Matrix, Female, Humans, Mice, Mice, Obese, Biological Sciences, Medical and Health Sciences, Medical biotechnology, Biomedical engineering
Abstract

Obesity and extracellular matrix (ECM) density are considered independent risk and prognostic factors for breast cancer. Whether they are functionally linked is uncertain. We investigated the hypothesis that obesity enhances local myofibroblast content in mammary adipose tissue and that these stromal changes increase malignant potential by enhancing interstitial ECM stiffness. Indeed, mammary fat of both diet- and genetically induced mouse models of obesity were enriched for myofibroblasts and stiffness-promoting ECM components. These differences were related to varied adipose stromal cell (ASC) characteristics because ASCs isolated from obese mice contained more myofibroblasts and deposited denser and stiffer ECMs relative to ASCs from lean control mice. Accordingly, decellularized matrices from obese ASCs stimulated mechanosignaling and thereby the malignant potential of breast cancer cells. Finally, the clinical relevance and translational potential of our findings were supported by analysis of patient specimens and the observation that caloric restriction in a mouse model reduces myofibroblast content in mammary fat. Collectively, these findings suggest that obesity-induced interstitial fibrosis promotes breast tumorigenesis by altering mammary ECM mechanics with important potential implications for anticancer therapies.

Published
2015

25. Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples

Author

Toomey, Sinead, Carr, Aoife, Mezynski, Mateusz Janusz, Elamin, Yasir, Rafee, Shereen, Cremona, Mattia, Morgan, Clare, Madden, Stephen, Abdul-Jalil, Khairun I., Gately, Kathy, Farrelly, Angela, Kay, Elaine W., Kennedy, Susan, O’Byrne, Kenneth, Grogan, Liam, Breathnach, Oscar, Morris, Patrick G., Eustace, Alexander J., Fay, Joanna, Cummins, Robert, O’Grady, Anthony, Kalachand, Roshni, O’Donovan, Norma, Kelleher, Fergal, O’Reilly, Aine, Doherty, Mark, Crown, John, and Hennessy, Bryan T.

Published
2020
Full Text
View/download PDF

30. Supplementary Data from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer

Author

Morris, Patrick G., primary, Zhou, Xi Kathy, primary, Milne, Ginger L., primary, Goldstein, Daniel, primary, Hawks, Laura C., primary, Dang, Chau T., primary, Modi, Shanu, primary, Fornier, Monica N., primary, Hudis, Clifford A., primary, and Dannenberg, Andrew J., primary

Published
2023
Full Text
View/download PDF

32. Data from A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease

Author

Gucalp, Ayca, primary, Zhou, Xi K., primary, Cook, Elise D., primary, Garber, Judy E., primary, Crew, Katherine D., primary, Nangia, Julie R., primary, Bhardwaj, Priya, primary, Giri, Dilip D., primary, Elemento, Olivier, primary, Verma, Akanksha, primary, Wang, Hanhan, primary, Lee, J. Jack, primary, Vornik, Lana A., primary, Mays, Carrie, primary, Weber, Diane, primary, Sepeda, Valerie, primary, O'Kane, Holly, primary, Krasne, Margaret, primary, Williams, Samantha, primary, Morris, Patrick G., primary, Heckman-Stoddard, Brandy M., primary, Dunn, Barbara K., primary, Hudis, Clifford A., primary, Brown, Powel H., primary, and Dannenberg, Andrew J., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Appendix 1 from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer

Author

Morris, Patrick G., primary, Zhou, Xi Kathy, primary, Milne, Ginger L., primary, Goldstein, Daniel, primary, Hawks, Laura C., primary, Dang, Chau T., primary, Modi, Shanu, primary, Fornier, Monica N., primary, Hudis, Clifford A., primary, and Dannenberg, Andrew J., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Tables 1 - 3 from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer

Author

Morris, Patrick G., primary, Zhou, Xi Kathy, primary, Milne, Ginger L., primary, Goldstein, Daniel, primary, Hawks, Laura C., primary, Dang, Chau T., primary, Modi, Shanu, primary, Fornier, Monica N., primary, Hudis, Clifford A., primary, and Dannenberg, Andrew J., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table 1 from A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease

Author

Gucalp, Ayca, primary, Zhou, Xi K., primary, Cook, Elise D., primary, Garber, Judy E., primary, Crew, Katherine D., primary, Nangia, Julie R., primary, Bhardwaj, Priya, primary, Giri, Dilip D., primary, Elemento, Olivier, primary, Verma, Akanksha, primary, Wang, Hanhan, primary, Lee, J. Jack, primary, Vornik, Lana A., primary, Mays, Carrie, primary, Weber, Diane, primary, Sepeda, Valerie, primary, O'Kane, Holly, primary, Krasne, Margaret, primary, Williams, Samantha, primary, Morris, Patrick G., primary, Heckman-Stoddard, Brandy M., primary, Dunn, Barbara K., primary, Hudis, Clifford A., primary, Brown, Powel H., primary, and Dannenberg, Andrew J., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 2 from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Author

Krop, Ian, primary, Abramson, Vandana, primary, Colleoni, Marco, primary, Traina, Tiffany, primary, Holmes, Frankie, primary, Garcia-Estevez, Laura, primary, Hart, Lowell, primary, Awada, Ahmad, primary, Zamagni, Claudio, primary, Morris, Patrick G., primary, Schwartzberg, Lee, primary, Chan, Stephen, primary, Gucalp, Ayca, primary, Biganzoli, Laura, primary, Steinberg, Joyce, primary, Sica, Lorenzo, primary, Trudeau, Maureen, primary, Markova, Denka, primary, Tarazi, Jamal, primary, Zhu, Zhou, primary, O'Brien, Thomas, primary, Kelly, Catherine M., primary, Winer, Eric, primary, and Yardley, Denise A., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 1B from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Author

Krop, Ian, primary, Abramson, Vandana, primary, Colleoni, Marco, primary, Traina, Tiffany, primary, Holmes, Frankie, primary, Garcia-Estevez, Laura, primary, Hart, Lowell, primary, Awada, Ahmad, primary, Zamagni, Claudio, primary, Morris, Patrick G., primary, Schwartzberg, Lee, primary, Chan, Stephen, primary, Gucalp, Ayca, primary, Biganzoli, Laura, primary, Steinberg, Joyce, primary, Sica, Lorenzo, primary, Trudeau, Maureen, primary, Markova, Denka, primary, Tarazi, Jamal, primary, Zhu, Zhou, primary, O'Brien, Thomas, primary, Kelly, Catherine M., primary, Winer, Eric, primary, and Yardley, Denise A., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Data from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Author

Krop, Ian, primary, Abramson, Vandana, primary, Colleoni, Marco, primary, Traina, Tiffany, primary, Holmes, Frankie, primary, Garcia-Estevez, Laura, primary, Hart, Lowell, primary, Awada, Ahmad, primary, Zamagni, Claudio, primary, Morris, Patrick G., primary, Schwartzberg, Lee, primary, Chan, Stephen, primary, Gucalp, Ayca, primary, Biganzoli, Laura, primary, Steinberg, Joyce, primary, Sica, Lorenzo, primary, Trudeau, Maureen, primary, Markova, Denka, primary, Tarazi, Jamal, primary, Zhu, Zhou, primary, O'Brien, Thomas, primary, Kelly, Catherine M., primary, Winer, Eric, primary, and Yardley, Denise A., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 3 from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Author

Krop, Ian, primary, Abramson, Vandana, primary, Colleoni, Marco, primary, Traina, Tiffany, primary, Holmes, Frankie, primary, Garcia-Estevez, Laura, primary, Hart, Lowell, primary, Awada, Ahmad, primary, Zamagni, Claudio, primary, Morris, Patrick G., primary, Schwartzberg, Lee, primary, Chan, Stephen, primary, Gucalp, Ayca, primary, Biganzoli, Laura, primary, Steinberg, Joyce, primary, Sica, Lorenzo, primary, Trudeau, Maureen, primary, Markova, Denka, primary, Tarazi, Jamal, primary, Zhu, Zhou, primary, O'Brien, Thomas, primary, Kelly, Catherine M., primary, Winer, Eric, primary, and Yardley, Denise A., primary

Published
2023
Full Text
View/download PDF

43. Biomineralogical signatures of breast microcalcifications

Author

Kunitake, Jennie A. M. R., primary, Sudilovsky, Daniel, additional, Johnson, Lynn M., additional, Loh, Hyun-Chae, additional, Choi, Siyoung, additional, Morris, Patrick G., additional, Jochelson, Maxine S., additional, Iyengar, Neil M., additional, Morrow, Monica, additional, Masic, Admir, additional, Fischbach, Claudia, additional, and Estroff, Lara A., additional

Published
2023
Full Text
View/download PDF

44. Neoadjuvant chemoradiation in elderly Irish patients with esophageal cancer: A review of the clinical outcomes and toxicity.

Author

Mc Laughlin, Ronan Andrew, primary, Almeraikhi, Majid, additional, Alkaabi, Humaid, additional, Bligh, Fianait, additional, Cluxton, Christopher, additional, Mcmahon, David, additional, Fitzpatrick, Orla, additional, Conroy, Michael R, additional, Hennessy, Bryan T., additional, O'Neill, Brian, additional, Naidoo, Jarushka, additional, Breathnach, Oscar S., additional, Grogan, William, additional, Murphy, Adrian Gerard, additional, and Morris, Patrick G., additional

Published
2023
Full Text
View/download PDF

45. A prospective translational study investigating the association of gut microbiome (GM) diversity with pathological complete response (pCR) after neoadjuvant treatment in early stage rectal and esophageal cancers.

Author

Mc Laughlin, Ronan Andrew, primary, Devoy, Ciaran, additional, moloney, carolyn, additional, Bennett, Kathleen, additional, Mcmahon, David, additional, Conroy, Michael R, additional, Fitzpatrick, Orla, additional, Egan, Keith, additional, Grogan, William, additional, Breathnach, Oscar S., additional, Morris, Patrick G., additional, Murphy, Adrian Gerard, additional, Naidoo, Jarushka, additional, Tangney, Mark, additional, and Hennessy, Bryan T., additional

Published
2023
Full Text
View/download PDF

46. Biomineralogical signatures of breast microcalcifications

Author

Massachusetts Institute of Technology. Department of Civil and Environmental Engineering, Kunitake, Jennie AMR, Sudilovsky, Daniel, Johnson, Lynn M, Loh, Hyun-Chae, Choi, Siyoung, Morris, Patrick G, Jochelson, Maxine S, Iyengar, Neil M, Morrow, Monica, Masic, Admir, Fischbach, Claudia, Estroff, Lara A, Massachusetts Institute of Technology. Department of Civil and Environmental Engineering, Kunitake, Jennie AMR, Sudilovsky, Daniel, Johnson, Lynn M, Loh, Hyun-Chae, Choi, Siyoung, Morris, Patrick G, Jochelson, Maxine S, Iyengar, Neil M, Morrow, Monica, Masic, Admir, Fischbach, Claudia, and Estroff, Lara A

Abstract

Microcalcifications, primarily biogenic apatite, occur in cancerous and benign breast pathologies and are key mammographic indicators. Outside the clinic, numerous microcalcification compositional metrics (e.g., carbonate and metal content) are linked to malignancy, yet microcalcification formation is dependent on microenvironmental conditions, which are notoriously heterogeneous in breast cancer. We interrogate multiscale heterogeneity in 93 calcifications from 21 breast cancer patients using an omics-inspired approach: For each microcalcification, we define a “biomineralogical signature” combining metrics derived from Raman microscopy and energy-dispersive spectroscopy. We observe that (i) calcifications cluster into physiologically relevant groups reflecting tissue type and local malignancy; (ii) carbonate content exhibits substantial intratumor heterogeneity; (iii) trace metals including zinc, iron, and aluminum are enhanced in malignant-localized calcifications; and (iv) the lipid-to-protein ratio within calcifications is lower in patients with poor composite outcome, suggesting that there is potential clinical value in expanding research on calcification diagnostic metrics to include “mineral-entrapped” organic matrix.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results